Navigation Links
Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
Date:11/1/2007

ents with stable coronary artery disease.

"I am very pleased with the results of this first clinical experience with the REG1 system during a stent procedure. We anticipate this drug will fulfill multiple unmet needs in the care of heart patients," stated Mauricio Cohen, MD, the Director of Cardiology Clinical Trials at the University of North Carolina and Principal Investigator of the REVERSAL-PCI study. "The lack of a safe and at the same time efficacious reversible blood thinner has been a major problem for cardiologists performing invasive catheterization procedures. We are hopeful that this agent will revolutionize the approach to anticoagulation during catheter-based interventions and the care of heart attack patients."

Currently, heparin and protamine are the only approved therapeutic/antidote drug pair used in surgical procedures, such as PCI. However, these drugs have well-known limitations, including the risk for developing heparin-induced thrombocytopenia (with or without thrombosis), as well as protamine-associated side effects, such as anaphylaxis and systemic hypotension.

About REG1 Anticoagulation System

Regado's lead product candidate, REG1, is the first specific, direct-acting, antidote-controlled anticoagulant ever described. Regado is developing REG1 for use in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures. These procedures, which include coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI), put patients at a high-risk for therapy-related bleeding complications. REG1 is being developed initially to increase therapeutic flexibility and improve patient outcomes in coronary revascularization procedures.

REG1 is a two-component system, consisting of an aptamer-based anticoagulant and its matched antidote. The REG1 anticoagulant component (RB006) is a single-stranded, nucleic acid aptamer. RB006 selectively and potently binds to and inhibits
'/>"/>

SOURCE Regado Biosciences
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013   Accuray Incorporated ... publication of study results involving hundreds of prostate ... System, the most widely used form of prostate ... 304 patients for a median of 5 years, ... that 97 percent of patients with low-risk and ...
(Date:5/21/2013)... ORLANDO, Fla. , May 21, 2013 /PRNewswire/ ... and safety results from the global Phase 3 ... protease inhibitor simeprevir (TMC435) led to sustained virologic ... (SVR12) in 79 percent of treatment-experienced genotype 1 ... disease, including all stages of liver fibrosis, when ...
(Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. ... analysis systems, announced today that Martin Mulroy ... the Stifel Annual Dental & Veterinary Conference on Wednesday, ... will be held at Le Parker Meridien Hotel in ... About Abaxis Abaxis develops, manufactures, markets and ...
Breaking Medicine Technology:New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2
... Sept. 9, 2011 Valeant Pharmaceuticals International, Inc. (" Valeant ... of Afexa Life Sciences Inc. (" Afexa ") its offer ... friendly offer (the " Offer ") for all of the ... at a price of C$0.71 in cash per Common Share. ...
... YORK, Sept. 8, 2011 NeoStem, Inc. (NYSE ... "Company"), an international biopharmaceutical company with a focus ... presenting at three upcoming September conferences: the Rodman ... Commercialization Summit, and the JMP Securities Healthcare Conference. ...
Cached Medicine Technology:Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa 2Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa 3Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa 4NeoStem Announces Participation in Multiple September Conferences 2NeoStem Announces Participation in Multiple September Conferences 3
(Date:5/21/2013)... A new study appearing in the current ... cells harvested from fat (adipose) are more potent than ... the body’s immune system. , The finding could ... adipose tissue-derived stem cells (AT-SCs) are far more plentiful ... and can be collected from waste material from liposuction ...
(Date:5/21/2013)... Idaho (PRWEB) May 21, 2013 The ... 26 million people in the United States of America ... patients are at a great risk of developing peripheral ... lead normal lives. The ADA further goes on saying ... 20 years and around 2 million new cases are ...
(Date:5/21/2013)... Australia (PRWEB) May 22, 2013 About ... made the Fertility Clinics industry one of ... industry assists patients who are unable to conceive naturally ... and popular of which is in-vitro fertilisation (IVF) cycles. ... IVF cycles in Australia has increased by 4.4% per ...
(Date:5/21/2013)... (HealthDay News) -- Aggressive treatment for prostate cancer ... with underlying medical conditions, a new study finds. ... radiation and radioactive seed implants, can cause serious ... and bowel problems, explained researchers from the University ... found that older patients with slower growing forms ...
(Date:5/21/2013)... University in St. Louis announced today that it ... funded by the Bill & Melinda Gates Foundation. ... environmental & chemical engineering, will pursue an innovative ... Killing of Parasite Eggs by Probiotic Organisms." , ... explore ideas that can break the mold in ...
Breaking Medicine News(10 mins):Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 2Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 3Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2Health News:Fertility Clinics in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Fertility Clinics in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Age, Other Illnesses May Make Prostate Cancer Treatment Unnecessary 2Health News:Gates Fellowship addresses parasite infection in developing world 2
... study has dismissed any association between consumption of dairy products ... total calcium intake//, and consequent changes in body weight. Diet ... calcium. ,More than 19,000 men between the age ... period. All of the study participants consumed a normal diet ...
... immense health benefits. Now, teens, who want that dream weight, ... keep obesity at bay, according to a new study. Researchers ... which combined yoga with breathing exercises certainly helped knock off ... and boys participated in a study. They were divided into ...
... of live chicken and eggs appear to have scaled ... initial fear of a bird flu outbreak abated.// ... Coordination Committee (NECC), “There has been some improvement in ... well as within the state in the last four ...
... report by the Canadian Institute for Health Information (CIHI) ... of money there has been no shortening of waiting ... said that the volume of diagnostic tests and high-priority ... care seems to have increased just as much. Statistics ...
... a new study claims that calcium intake was not associated ... study was published in the American Journal of Clinical Nutrition. ... who were enrolled in the Health Professionals Follow-up Study were ... and relation between total calcium intake from diet and supplements ...
... disease in eastern Sarawak state of Malaysia is causing concern ... shut down all schools in the area to prevent the ... virus, which causes the disease, has so far affected more ... it. "In peninsular Malaysia, the health ministry will take a ...
Cached Medicine News:
2.5x8mm Spatula Combined with 8mm Blade; in stainless steel....
0.6mm Tip x10mm Shaft, Straight Shaft, 90 Degree Hook at Tip; overall length 120mm; in Titianium....
Bend with "H" Shaped Tip, Right; Stainless Steel....
... Perfusion Catheter is indicated for ... portion of a coronary artery ... the purpose of improving myocardial ... are also designed to provide ...
Medicine Products: